The average life expectancy span of Human Beings are increased due to better medical facilities and drugs developed by Biopharma companies. Pharmaceutical products or drugs or medicines are being produced […]readmore
Tags : Celgene
The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were […]readmore
The US FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 35 new products so far in 2019. In 2018 FDA […]readmore
Roche’s Kadcyla (trastuzumab emtansine) Receives CHMP’s Recommendation for Approval as an Adjuvant Treatment for Patients with HER2+ eBC with Residual Invasive Disease After Neoadjuvant Treatment Published: Nov 15, 2019 | Tags: […]readmore
Shots: Skyhawk to receive $80M up front, milestones, and royalties on sales. Celgene to get exclusive WW option to license IPR for the number of Skyhawk’s candidates targeting multiple autoimmune […]readmore
Shots: Editas to receive $70M up front, milestone and royalty payments for each therapy developed by Celgene and will develop genome editing tool for which Celgene has right to opt-in […]readmore
Shots: The approval is based on P-III BELIEVE study assessing Reblozyl (1.0 mg/kg, SC) + BSC vs PBO + BSC in 336 patients in a ratio (2:1) requiring RBC transfusions […]readmore
Biopharma acquisition activity in 2018 shows a significant increase over the previous year. Takeda proved to be on top with the acquisition of Shire among the top 20 acquisitions with […]readmore
The US FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 31 new products so far in 2019. In 2018 FDA […]readmore
1. Eisai And Biogen to Terminate Two P-III Clinical Studies of Elenbecestat (E2609) for Early Alzheimer’s Disease Published: Sept 13, 2019 | Tags: Eisai, Biogen, Terminate Two, P-III, Clinical Studies, Elenbecestat, […]readmore